With the mission to translate scientific innovation into a life-saving medical procedure, Dr. Luhan Yang is leading a team of world-renowned scientists to leverage CRISPR technology and its potential to deliver safe and effective human transplantable organs to the hundreds of thousands of patients worldwide who are in dire need.

In the US alone, more than 116,000 people annually are in need of a lifesaving organ transplant, and 20 people die every day waiting for a transplant. To address this issue, scientists have been trying to engineer animal organs for human transplantation for more than 100 years. However, concern for issues such as pig-to-human immunological compatibility and cross-species transmission of porcine endogenous retroviruses (PERV) have proven to be two insurmountable obstacles -- until now.

In a breakthrough paper published in Science, Yang and her team demonstrated for the first time the inactivation of PERV to prevent cross-species viral transmission, an important milestone for xenotransplantation. As co-founder and chief scientific officer, Yang has been at the center of eGenesis' success. In addition to recruiting and leading a high-caliber scientific team, she has played an integral role in daily management of the company, business strategy and planning, as well as negotiating with investors for early round funding.

Yang holds BS degrees in biology and psychology from Peking University and a PhD in human biology and translational medicine from Harvard Medical School.